希瑪眼科(03309.HK)擬3887.5萬港元攬Avalon Global 5%股權 後者目前正在研發流感疫苗
格隆匯1月20日丨希瑪眼科(03309.HK)公佈，於2020年1月20日，希瑪投資已與Avalon Global訂立認購協議，據此，希瑪投資同意認購Avalon Global 經擴大後5%股份，代價為3887.5萬港元，部分以現金結算及部分由公司向Avalon Global發行386.43萬股代價股份結算。 代價股份每股發行價5.03港元，較1月20日收市價折讓約3.6%。
據悉，Avalon Global為一間投資控股公司，及其附屬公司主要從事開發下一代醫療保健解決方案業務以造福人類並從涵蓋生物製藥、診斷、醫療器械等其他醫療保健領域提高壽命。Avalon Global目前正在研發流感疫苗。
希瑪集團擁有一支實力雄厚的眼科醫生隊伍，為開發和投資眼科技術投入專業的支援。認購Avalon Global，可以將其先進的技術與集團豐富的醫生資源相結合，實現技術理念與臨牀實踐之間的相輔相承以及優化轉化，為患者提供更人性化的優質治療方案。
集團董事會認為，認購Avalon Global符合集團的整體業務範圍和方向，也為未來集團投資生命科學產品和技術提供了一個良機。公司認為，無論在中國內地還是中國香港地區，乃至在全球範圍內，這些技術和產品都具備巨大的發展潛力。同時，公司亦相信，通過充分發掘和發揮其潛力，Avalon Global將開拓出更廣闊的進步空間。
在認購完成後，集團將繼續與醫療專業人士合作，專注於優質醫療服務以及藥物開發等領域，以構建一個連貫性強、整合度高的醫療服務網路。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
